Programmed Death Ligand 1 (PD-L1) immunotherapy has been successful in the treatment of lung cancer, urothelial carcinoma and other tumors, bringing hope for the treatment of pancreatic cancer 5. Here, CD274 is linked to familial pancreatic carcinoma.